EGFR and neoplasm: In vivo NIRF imaging of mice at various postinjection time points from 0 to 24 h obtained consistent results showing different tumor accumulation behaviors of the Alexa Fluor 750-labeled scAb-EGFR-targeted nanomedicine (TSV) and nontargeted nanomedicine (NSV group) administered via the tail vein (Fig. 4b, Supplementary Fig. 10).